Shaurya Mahajan

Mr. Shaurya Mahajan


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
YMYatharth Mahajan
Yatharth Mahajan
SMShaurya Mahajan
Shaurya Mahajan
Alireza SharafshahAlireza Sharafshah
Alireza Sharafshah
KSKeerthy Sunder
Keerthy Sunder
Kai-Uwe LewandrowskiKai-Uwe Lewandrowski
Kai-Uwe Lewandrowski
KBKenneth Blum
Kenneth Blum
Background: GLP‑1 receptor agonists (GLP‑1RAs) are effective for type 2 diabetes and obesity and engage central stress and reward pathways (HPA axis; mesolimbic dopamine). Psychiatric signals have been reported in some settings. Objective :To narratively synthesize evidence on neuropsychiatric effects of GLP‑1RAs—mood, anxiety, suicidality, reward processing, substance use, and migraine—and to consider genetic/epigenetic moderators (e.g., hypodopaminergia/reward deficiency syndrome).Evidence: Mechanistic and imaging studies demonstrate GLP‑1 engagement of HPA and reward circuitry; animal work suggests acute anxiogenic responses with mixed chronic effects. Pharmacovigilance datasets (FAERS/EudraVigilance) show signals for headache, dizziness, sensory changes, and less consistently for depression/anxiety/suicidality; such data are hypothesis‑generating and not causal. Clinical trials and meta‑analyses report heterogeneous outcomes, including small antidepressant effects in some T2DM cohorts. Conclusions: Neuropsychiatric outcomes with GLP‑1RAs appear context‑dependent. Individuals with hypodopaminergic biology may be vulnerable to reward blunting/anxiety, whereas others may experience mood benefits. A pragmatic approach is screen–stratify–monitor, with slow titration and prompt adjustment if psychiatric signals emerge. Prospective, genotype‑informed studies are needed to identify who benefits or is harmed and why.